ARS Pharmaceuticals, Inc. (SPRY) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Ars Pharmaceuticals, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.759 I now turn the call over to Justin Shakma, Chief Business Officer. 00:00:04.759 -- 00:00:07.180 Please proceed. 00:00:08.325 -- 00:00:13.635 Good morning, and thank you for joining our first quarter 2025 earnings conference call. 00:00:13.635 -- 00:00:17.702 This morning, we issued a press release detailing our financial results and commercial 00:00:17.702 -- 00:00:24.470 highlights, which is available in the investor and media section of our website at ars-pharma.com. 00:00:25.141 -- 00:00:29.887 With me on the call are Richard Lowenthal, our co-founder, president, and CEO, who will 00:00:29.887 -- 00:00:33.232 review recent corporate updates and achievements. 00:00:33.232 -- 00:00:38.118 Eric Peraz, our chief commercial officer, who will cover our commercial activities and 00:00:38.118 -- 00:00:39.880 progress. 00:00:39.880 -- 00:00:44.686 And Kathy Scott, our CFO, who will provide a summary of our financial results and cash 00:00:44.686 -- 00:00:46.369 position. 00:00:46.369 -- 00:00:51.716 Before we begin, please note that today's remarks may contain forward-looking statements. 00:00:51.716 -- 00:00:57.012 Actual results may differ materially. Please refer to our press release and SEC 00:00:57.012 -- 00:00:59.616 filings for further risk disclosures. 00:00:59.616 -- 00:01:03.181 With that, I'll turn the call over to Rich. 00:01:03.181 -- 00:01:08.088 Thank you, Justin. Good morning, and thank you all for joining us on this call. 00:01:08.088 -- 00:01:11.573 We're off to a strong start in 2025 00:01:11.573 -- 00:01:16.661 as we continue to execute the nationwide launch of NEFI, the first and only needle-free 00:01:16.661 -- 00:01:21.841 epinephrine treatment approved for type 1 allergic reactions, including anaphylaxis. 00:01:21...